title: Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
abstract: Purpose:Whether isocitrate dehydrogenase (IDH) gene aberrations affected prognosis of patients with acute myeloid leukemia (AML) was controversial. Here, we conducted a meta-analysis to evaluate their prognostic value.Experimental Design:PubMed, Embase, Cochrane, and Chinese databases were searched to identify studies exploring howIDHgene aberrations affected AML outcome. Pooled HRs and relative risks (RR) were calculated, along with 95% confidence intervals (CI).Results:Thirty-three reports were included.IDHmutations seemed not to affect overall survival (OS: HR, 1.05; 95% CI, 0.89-1.23) and event-free survival (EFS: HR, 0.97; 95% CI, 0.80-1.18) when considered as a single factor, but improved accumulative incidence of relapse (CIR: HR, 1.44; 95% CI, 1.18-1.76) in patients with intermediate-risk karyotypes (IR-AML). However,IDH1mutation conferred worse OS (HR, 1.17; 95% CI, 1.05-1.31) and EFS (HR, 1.29; 95% CI, 1.07-1.56), especially in patients with normal cytogenetics (OS: HR, 1.21; 95% CI, 1.01-1.46; EFS: HR, 1.56; 95% CI, 1.23-1.98). Prognosis of theIDH1single-nucleotide polymorphism rs11554137 was also poor (OS: HR, 1.34; 95% CI, 1.03-1.75).IDH2mutation improved OS (HR, 0.78; 95% CI, 0.66-0.93), particularly in IR-AML patients (OS: HR, 0.65; 95% CI, 0.49-0.86). TheIDH2 (R140)mutation was associated with better OS among younger cases (HR, 0.64; 95% CI, 0.49-0.82). Treatment outcome was poor [RR for complete remission rates inIDH1mutation: 1.21; 95% CI, 1.02-1.44;IDH2(R172) mutation: 2.14; 95% CI, 1.61-2.85].Conclusions:Various subtypes ofIDHmutations might contribute to different prognosis and be allowed to stratify IR-AML further.Clin Cancer Res; 23(15); 4511-22. ©2017 AACR.
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.|Medical School of Nankai University, Tianjin, China.
authors.forename: Qingyu
authors.initials: Q
authors.lastname: Xu
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Na
authors.initials: N
authors.lastname: Lv
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yihan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yuyan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Zilong
authors.initials: Z
authors.lastname: Yao
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.|Medical School of Nankai University, Tianjin, China.
authors.forename: Xiaosu
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Sai
authors.initials: S
authors.lastname: Huang
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yonghui
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology and BMT Center, Chinese PLA General Hospital, Beijing, China. liyu301@vip.163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology* / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D007521:Isocitrate Dehydrogenase